Literature DB >> 12368667

Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade.

William R Jarnagin1, Mithat Gonen, Yuman Fong, Ronald P DeMatteo, Leah Ben-Porat, Sarah Little, Carlos Corvera, Sharon Weber, Leslie H Blumgart.   

Abstract

OBJECTIVE: To assess the nature of changes in the field of hepatic resectional surgery and their impact on perioperative outcome.
METHODS: Demographics, extent of resection, concomitant major procedures, operative and transfusion data, complications, and hospital stay were analyzed for 1,803 consecutive patients undergoing hepatic resection from December 1991 to September 2001 at Memorial Sloan-Kettering Cancer Center. Factors associated with morbidity and mortality and trends in operative and perioperative variables over the period of study were analyzed.
RESULTS: Malignant disease was the most common diagnosis (1,642 patients, 91%); of these cases, metastatic colorectal cancer accounted for 62% (n = 1,021). Three hundred seventy-five resections (21%) were performed for primary hepatic or biliary cancers and 161 (9%) for benign disease. Anatomical resections were performed in 1,568 patients (87%) and included 544 extended hepatectomies, 483 hepatectomies, and 526 segmental resections. Sixty-two percent of patients had three or more segments resected, 42% had bilobar resections, and 37% had concomitant additional major procedures. The median blood loss was 600 mL and 49% of patients were transfused at any time during the index admission. Median hospital stay was 8 days, morbidity was 45%, and operative mortality was 3.1%. Over the study period, there was a significant increase in the use of parenchymal-sparing segmental resections and a decrease in the number of hepatic segments resected. In parallel with this, there was a significant decline in blood loss, the use of blood products, and hospital stay. Despite an increase in concomitant major procedures, operative mortality decreased from approximately 4% in the first 5 years of the study to 1.3% in the last 2 years, with 0 operative deaths in the last 184 consecutive cases. On multivariate analysis, the number of hepatic segments resected and operative blood loss were the only independent predictors of both perioperative morbidity and mortality.
CONCLUSIONS: Over the past decade, the use of parenchymal-sparing segmental resections has increased significantly. The number of hepatic segments resected and operative blood loss were the only predictors of both perioperative morbidity and mortality, and reductions in both are largely responsible for the decrease in perioperative mortality, which has occurred despite an increase in concomitant major procedures.

Entities:  

Mesh:

Year:  2002        PMID: 12368667      PMCID: PMC1422593          DOI: 10.1097/01.SLA.0000029003.66466.B3

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  A prospective analysis of staging laparoscopy in patients with primary and secondary hepatobiliary malignancies.

Authors:  W R Jarnagin; J Bodniewicz; E Dougherty; K Conlon; L H Blumgart; Y Fong
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

3.  [Well defined technic for right hepatectomy].

Authors:  J L LORTAT-JACOB; H G ROBERT
Journal:  Presse Med       Date:  1952-04-16       Impact factor: 1.228

4.  Management of 155 patients with benign liver tumours.

Authors:  C K Charny; W R Jarnagin; L H Schwartz; H S Frommeyer; R P DeMatteo; Y Fong; L H Blumgart
Journal:  Br J Surg       Date:  2001-06       Impact factor: 6.939

5.  Solid liver tumors.

Authors:  J H Foster; M M Berman
Journal:  Major Probl Clin Surg       Date:  1977

6.  A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases.

Authors:  W R Jarnagin; K Conlon; J Bodniewicz; E Dougherty; R P DeMatteo; L H Blumgart; Y Fong
Journal:  Cancer       Date:  2001-03-15       Impact factor: 6.860

7.  Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection.

Authors:  J Belghiti; K Hiramatsu; S Benoist; P Massault; A Sauvanet; O Farges
Journal:  J Am Coll Surg       Date:  2000-07       Impact factor: 6.113

8.  Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases.

Authors:  R P DeMatteo; C Palese; W R Jarnagin; R L Sun; L H Blumgart; Y Fong
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

9.  Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors.

Authors:  T J Gayowski; S Iwatsuki; J R Madariaga; R Selby; S Todo; W Irish; T E Starzl
Journal:  Surgery       Date:  1994-10       Impact factor: 3.982

10.  One hundred consecutive hepatic resections. Blood loss, transfusion, and operative technique.

Authors:  J D Cunningham; Y Fong; C Shriver; J Melendez; W L Marx; L H Blumgart
Journal:  Arch Surg       Date:  1994-10
View more
  514 in total

1.  Coagulation profile changes and safety of epidural analgesia after hepatectomy: a retrospective study.

Authors:  Kelly G Elterman; Zhiling Xiong
Journal:  J Anesth       Date:  2014-11-13       Impact factor: 2.078

Review 2.  Pre-resectional inflow vascular control: extrafascial dissection of Glissonean pedicle in liver resections.

Authors:  Aleksandar Karamarković; Krstina Doklestić
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 3.  Post-hepatectomy liver failure.

Authors:  Rondi Kauffmann; Yuman Fong
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

4.  Laparoscopic parenchymal-sparing liver resection of lesions in the central segments: feasible, safe, and effective.

Authors:  Claudius Conrad; Satoshi Ogiso; Yosuke Inoue; Nairuthya Shivathirthan; Brice Gayet
Journal:  Surg Endosc       Date:  2014-11-13       Impact factor: 4.584

5.  Factors in perioperative care that determine blood loss in liver surgery.

Authors:  Stephen J McNally; Erica J Revie; Lisa J Massie; Dermot W McKeown; Rowan W Parks; O James Garden; Stephen J Wigmore
Journal:  HPB (Oxford)       Date:  2012-02-28       Impact factor: 3.647

6.  Low-dose steroid pretreatment ameliorates the transient impairment of liver regeneration.

Authors:  Toshihito Shibata; Toru Mizuguchi; Yukio Nakamura; Masaki Kawamoto; Makoto Meguro; Shigenori Ota; Koichi Hirata; Hidekazu Ooe; Toshihiro Mitaka
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

7.  Safe major abdominal operations: hepatectomy, gastrectomy and pancreatoduodenectomy in elder patients.

Authors:  Yu-Lian Wu; Jun-Xiu Yu; Bin Xu
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

8.  Population-based review of the outcomes following hepatic resection in a Canadian health region.

Authors:  Elijah Dixon; Oliver F Bathe; Andrew McKay; Isabelle You; Scot Dowden; David Sadler; Kelly W Burak; J Gregory McKinnon; Walter Miller; Francis R Sutherland
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

9.  The role of liver resection in patients with metastatic breast cancer: a systematic review examining the survival impact.

Authors:  Sadia Tasleem; Jarlath C Bolger; Michael E Kelly; Michael R Boland; Dermot Bowden; Karl J Sweeney; Carmel Malone
Journal:  Ir J Med Sci       Date:  2018-02-01       Impact factor: 1.568

10.  Prealbumin is predictive for postoperative liver insufficiency in patients undergoing liver resection.

Authors:  Liang Huang; Jing Li; Jian-Jun Yan; Cai-Feng Liu; Meng-Chao Wu; Yi-Qun Yan
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.